Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283382 · ClinicalTrials.gov registry record · Early Phase 1
Cannabidiol Effects on Learning and Anxiety
A Early Phase 1 study of Anxiety and Fear, sponsored by University of Connecticut.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT05283382 is a Early Phase 1 study of Anxiety and Fear that is actively recruiting participants, run by University of Connecticut. The registered enrollment target is 160 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05283382, a Early Phase 1 study of Anxiety and Fear, is actively recruiting participants, sponsored by University of Connecticut.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety. Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut. All participants will be put in a standard fear conditioning paradigm where they are conditioned to fear a face that occasionally is followed by a shock to their wrist. The other face never is paired with a shock. After everybody learns this, half of the participants will receive 600 mg CBD Isolate Gel Capsules one time, and the other half will receive a placebo dose. Participants will then be presented with the faces with no shocks, and the rate and duration of extinction as measured by electrodermal response as well as subjective fear ratings via a visual analogue scale will be examined. It is hypothesized that participants that receive CBD will display enhanced extinction compared to the placebo group, as evidenced by reduced electrodermal response and reduced visual analogue fear ratings.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Cannabidiol Oral Product
Study Locations (1)
Connecticut
- University of Connecticut - Storrs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2024-10-30 |
| Est. Completion | 2026-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05283382
The ClinicalTrials.gov registry entry for NCT05283382 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Connecticut, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anxiety and Fear appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05283382 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05283382 about?
NCT05283382 is a clinical study titled "Cannabidiol Effects on Learning and Anxiety". To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety. Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut. All participants will be p...
What is the current status of trial NCT05283382?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 160 participants. The study started on 2024-10-30. Estimated completion is 2026-02.
What conditions does trial NCT05283382 study?
This clinical trial studies the following conditions: Anxiety and Fear.
What interventions are being tested in trial NCT05283382?
The interventions under investigation include: Placebo (OTHER), Cannabidiol Oral Product (DRUG).
Who is sponsoring clinical trial NCT05283382?
This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05283382 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety and Fear
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.